Drug Trial Radar · NCT05112601
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
81
Planned (sponsor's estimate)
Start
Jun 2, 2022
Primary completion
Jul 30, 2032
Study completion Jul 30, 2032
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- Collaborators
- NRG Oncology
- First posted
- Nov 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period of time during which the cancer could not be detected (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing damaged DNA. In 2-3% of endometrial cancers this may be due to a hereditary condition resulted from gene mutation called Lynch Syndrome (previously called hereditary nonpolyposis colorectal cancer or HNPCC). MMR deficient cells usually have many DNA mutations. Tumors that have evidence of mismatch repair deficiency tend to be more sensitive to immunotherapy. There is some evidence that nivolumab with ipilimumab can shrink or stabilize cancers with deficient mismatch repair system. However, it is not known whether this will happen in endometrial cancer; therefore, this study is designed to answer that question. Monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab in combination with ipilimumab may be better than nivolumab alone in treating dMMR recurrent endometrial carcinoma.
Conditions
- Endometrial Adenocarcinoma
- Endometrial Clear Cell Adenocarcinoma
- Endometrial Dedifferentiated Carcinoma
- Endometrial Endometrioid Adenocarcinoma
- Endometrial Mixed Cell Adenocarcinoma
- Endometrial Mucinous Adenocarcinoma
- Endometrial Undifferentiated Carcinoma
- Endometrioid Adenocarcinoma
- Recurrent Endometrial Carcinoma
Interventions
Biospecimen CollectionProcedure
Undergo collection of tissue and/or blood samples
Computed TomographyProcedure
Undergo CT
IpilimumabBiological
Given IV
Magnetic Resonance ImagingProcedure
Undergo MRI
NivolumabBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years after randomization
Locations
138 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama · Recruiting
University Cancer and Blood Center LLC
Athens, Georgia · Suspended
Augusta University Medical Center
Augusta, Georgia · Recruiting
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho · Suspended
Saint Luke's Cancer Institute - Boise
Boise, Idaho · Recruiting
Saint Alphonsus Cancer Care Center-Caldwell
Caldwell, Idaho · Suspended
Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho · Recruiting
Saint Luke's Cancer Institute - Fruitland
Fruitland, Idaho · Recruiting
Saint Luke's Cancer Institute - Meridian
Meridian, Idaho · Recruiting
Saint Alphonsus Cancer Care Center-Nampa
Nampa, Idaho · Suspended
Saint Luke's Cancer Institute - Nampa
Nampa, Idaho · Recruiting
Kootenai Clinic Cancer Services - Post Falls
Post Falls, Idaho · Recruiting
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, Idaho · Recruiting
University of Illinois
Chicago, Illinois · Suspended
Carle at The Riverfront
Danville, Illinois · Recruiting
Carle Physician Group-Effingham
Effingham, Illinois · Recruiting
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois · Recruiting
Carle BroMenn Medical Center
Normal, Illinois · Recruiting
Carle Cancer Institute Normal
Normal, Illinois · Recruiting
Carle Cancer Center
Urbana, Illinois · Recruiting
IU Health North Hospital
Carmel, Indiana · Suspended
Northwest Cancer Center - Crown Point
Crown Point, Indiana · Recruiting
Northwest Oncology LLC
Dyer, Indiana · Recruiting
Northwest Cancer Center - Hobart
Hobart, Indiana · Recruiting
Saint Mary Medical Center
Hobart, Indiana · Recruiting
Indiana University/Melvin and Bren Simon Cancer Center
Indianapolis, Indiana · Recruiting
Saint Catherine Hospital
Indianapolis, Indiana · Recruiting
The Community Hospital
Munster, Indiana · Recruiting
Women's Diagnostic Center - Munster
Munster, Indiana · Recruiting
Northwest Cancer Center - Valparaiso
Valparaiso, Indiana · Recruiting
University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa · Recruiting
The James Graham Brown Cancer Center at University of Louisville
Louisville, Kentucky · Recruiting
UofL Health Medical Center Northeast
Louisville, Kentucky · Recruiting
MaineHealth Maine Medical Center- Scarborough
Scarborough, Maine · Recruiting
Bronson Battle Creek
Battle Creek, Michigan · Recruiting
Corewell Health Grand Rapids Hospitals - Butterworth Hospital
Grand Rapids, Michigan · Recruiting
Trinity Health Grand Rapids Hospital
Grand Rapids, Michigan · Suspended
Bronson Methodist Hospital
Kalamazoo, Michigan · Recruiting
West Michigan Cancer Center
Kalamazoo, Michigan · Recruiting
Beacon Kalamazoo Cancer Center
Kalamazoo, Michigan · Recruiting
Showing 40 of 138 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.